FDA Grants Groundbreaking Pioneering Approval for Opdivo Qvantig Injection in 5 Adult Solid Tumor Indications
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection for subcutaneous use. This innovative combination product…
Lilly Applauds ITC Ruling on Counterfeit Tirzepatide Imports 2024
In a significant victory for patient safety, the judge presiding over Eli Lilly’s case before the International Trade Commission (ITC) ruled that U.S. Customs and Border Protection should block the…
Aetna Launches Spanish Support for Health App to Serve Diverse Communities
Aetna , a CVS Health® company , has enhanced the functionality of its Aetna Health℠ app to offer Spanish language support for all eligible health plan members, regardless of their…
Regeneron Advances Factor XI Antibodies to Phase 3 After Positive Phase 2 Results
Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets…
Merck Invests €120M in Shizuoka Advanced Materials Center
Merck, a leading science and technology company, announced plans to invest over €70 million in constructing a new Advanced Materials Development Center (AMDC) at its Shizuoka site in Japan. This…
Roche Prasinezumab Shows Potential in Early Parkinson’s Despite Phase IIb Miss
Roche has announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Participants received treatment for a minimum of 18 months while maintaining…
Merck Reports Phase 3 Results for DOR/ISL HIV Treatment
Merck known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of…
WHO Academy Launched by Marcron And World Health Organization Leaders
The World Health Organization WHO Academy in Lyon, France, officially opened its doors yesterday with a grand inauguration ceremony. The event was graced by French President Emmanuel Macron, WHO Director-General…
Hansoh Licenses GLP-1 Agonist HS-10535 to MSD Globally
Hansoh Pharma has granted MSD (the tradename of Merck & Co., Inc., Rahway, N.J., USA) an exclusive global license for HS-10535, its investigational oral small molecule GLP-1 receptor agonist. This…
Viatris Publishes Phase 2b CARE Study Data on Cenerimod in Lancet Rheumatology
Viatris announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The findings, published in Lancet…
Teva and Sanofi Announce Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease
Teva Pharmaceuticals and Sanofi today announced that the Phase 2b RELIEVE UCCD study of duvakitug (TEV’574/SAR447189), an anti-TL1A monoclonal antibody, met its primary endpoints for the treatment of moderate-to-severe ulcerative…
Aflibercept 8 mg Phase III Study Shows Vision Gains with Extended Treatment Intervals in Retinal Vein Occlusion
Bayer announced positive topline results from the global Phase III QUASAR study, which evaluated the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein…